Pensilvānijā bāzētā JBS Science šodien paziņoja, ka tā ir saņēmusi 3 miljonu ASV dolāru Bridge Award balvu par mazo uzņēmumu inovāciju pētniecību IIB no Nacionālā vēža institūta. Uzņēmums izstrādāja pirmo šķidro biopsijas produktu, kas ir urīna DNS skrīnings agrīnai aknu šūnu vēža (HCC) noteikšanai.
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of aknu vēzis. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating audzējs DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS paziņoja, ka tā ir sadarbojusies ar Džeimsu Hamiltonu no Džona Hopkinsa Universitātes Medicīnas centra un Hie-Won Hann no Tomasa Universitātes slimnīcas, lai veicinātu aknu vēža urīna testa attīstību.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
